Cite
PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL
MLA
Jennings, Lisa K., et al. “Pharmacodynamics of Vorapaxar, a Platelet Par-1 Antagonist, and Its Interaction with P2y12 Receptor Pathway in the Tracer Trial.” Journal of the American College of Cardiology (JACC), vol. 59, Mar. 2012, p. E351. EBSCOhost, https://doi.org/10.1016/S0735-1097(12)60352-0.
APA
Jennings, L. K., Moliterno, D., Storey, R., Hord, E., Kotha, J., Becker, R., Smyth, S., Providencia, L., Moccetti, T., Valgimigli, M., Dery, J.-P., Cornel, J. H., Thomas, G., Huber, K., Chen, E., Strony, J., Rorick, T., Tricoci, P., & Mahaffey, K. (2012). Pharmacodynamics of Vorapaxar, a Platelet Par-1 Antagonist, and Its Interaction with P2y12 Receptor Pathway in the Tracer Trial. Journal of the American College of Cardiology (JACC), 59, E351. https://doi.org/10.1016/S0735-1097(12)60352-0
Chicago
Jennings, Lisa K., David Moliterno, Robert Storey, Edward Hord, Jayaprakash Kotha, Richard Becker, Susan Smyth, et al. 2012. “Pharmacodynamics of Vorapaxar, a Platelet Par-1 Antagonist, and Its Interaction with P2y12 Receptor Pathway in the Tracer Trial.” Journal of the American College of Cardiology (JACC) 59 (March): E351. doi:10.1016/S0735-1097(12)60352-0.